Calcipotriene is a vitamin D analog indicated for the treatment of plaque psoriasis in adults. It is available as ointment, cream and foam for topical use. MedsAcross supplies Calcipotriene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Calcipotriene Ointment, 0.005%, is indicated for the treatment of plaque psoriasis in adults. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.
Source: US FDA prescribing information
Apply a thin layer of Calcipotriene Ointment once or twice daily and rub in gently and completely.
Source: US FDA prescribing information
Calcipotriene Ointment is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene Ointment should not be used on the face.
Source: US FDA prescribing information
Contact dermatitis, including allergic contact dermatitis, has been observed with the use of Calcipotriene Ointment.
Source: US FDA prescribing information
Clinical Trials Experience In controlled clinical trials, the most frequent adverse reactions reported for Calcipotriene Ointment were burning, itching and skin irritation, which occurred in approximately 10-15% of patients. Erythema, dry skin, peeling, rash, dermatitis, worsening of psoriasis including development of facial/scalp psoriasis were reported in 1 to 10% of patients. Other experiences reported in less than 1% of patients included skin atrophy, hyperpigmentation, hypercalcemia, and folliculitis. Once daily dosing has not been shown to be superior in safety to twice daily dosing. Postmarketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Source: US FDA prescribing information
Store at controlled room temperature 15°C-25°C (59°F-77°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
7 presentations of Calcipotriene, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Calcipotriene 50 mcg/g ointmentTopicalGeneric name | — | US FDA | Available on request |
| Calcipotriene 50 mcg/g creamTopicalGeneric name | — | US FDA | Available on request |
| Calcitrene 0.005% ointmentTopical | Sun Pharmaceutical IndustriesIndia | US FDA | Available on request |
| Calcipotriene 0.05 mg/mL topical solutionTopicalGeneric name | — | US FDA | Available on request |
| Calcipotriene 50 mcg/g foamTopicalGeneric name | — | US FDA | Available on request |
| Pellix 0.05 mg/mL topical solutionTopical | Perfero Pharma | US FDA | Available on request |
| Sorilux 50 mcg/g foamTopical | Mayne Pharma | US FDA | Available on request |
3 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 29 December 1993 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Calcipotriene in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 7 presentations of Calcipotriene and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Sun Pharmaceutical Industries.
The catalogue lists 3 brand names for Calcipotriene, including Calcitrene, Pellix, Sorilux.
Yes. The US FDA first approved Calcipotriene on 29 December 1993, according to Drugs@FDA.
No listed presentation of Calcipotriene is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Calcipotriene is classified under ATC code D05AX02 (Calcipotriene).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.